We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.
- Authors
Shamloo, Behrooz K; Chhabra, Pankdeep; Freedman, Andrew N; Potosky, Arnold; Malin, Jennifer; Weiss Smith, Sheila
- Abstract
Bevacizumab is the first in its class, vascular endothelial growth factor (VEGF) inhibitor that was initially approved by the US FDA in 2004 for the treatment of metastatic colon cancer and other solid tumors. Preapproval clinical trials, particularly for oncology drugs, are limited in their ability to detect certain adverse effects and, therefore, the FDA and pharmaceutical sponsors collect and monitor reports of adverse events (AEs) following approval.
- Publication
Drug safety, 2012, Vol 35, Issue 6, p507
- ISSN
1179-1942
- Publication type
Journal Article
- DOI
10.2165/11597600-000000000-00000